NEW
Stock Screener with Intrinsic Value
Protagonist Therapeutics, Inc. (PTGX)
Last Price$37.2(1.6%)
Market Cap$2,297.8M
WACC
11.4%
Cost of Equity
11.4%
Cost of Debt
0.0%
Debt to Equity
0.5%
Beta
1.0
Stock quality
7/10
Great
PTGX WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
PTGX Cost of Equity
Crunching data... Almost there!
PTGX vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Protagonist Therapeutics, Inc.PTGX
11.4%
125.7%
(44.8%)
(131.6%)
Median Peer Set
7.6%
15.4%
(15.2%)
12.2%
Moderna, Inc.MRNA
10.5%
(64.4%)
N/A
(68.8%)
Summit Therapeutics Inc.SMMT
7.8%
(100.0%)
160.5%
N/A
BioNTech SEBNTX
7.7%
(77.4%)
(89.7%)
24.4%
Vertex Pharmaceuticals IncorporatedVRTX
7.7%
10.5%
8.3%
36.7%
Novo Nordisk A/SNVO
7.6%
34.5%
(21.9%)
36.0%
United Therapeutics CorporationUTHR
7.6%
20.2%
31.7%
42.3%
Alnylam Pharmaceuticals, Inc.ALNY
7.6%
76.2%
(62.2%)
(24.1%)
Regeneron Pharmaceuticals, Inc.REGN
7.5%
7.8%
(8.5%)
30.1%
BeiGene, Ltd.BGNE
4.9%
73.7%
(56.5%)
(35.9%)
argenx SEARGX
negative
198.6%
(60.5%)
(24.1%)
Explore more intrinsic value tools hub for PTGX
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Protagonist Therapeutics, Inc.'s discount rate as of Feb 03, 2025?
As of Feb 03, 2025, Protagonist Therapeutics, Inc.'s discount rate is 11.39%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Protagonist Therapeutics, Inc.'s capital structure and risk profile.
What is Protagonist Therapeutics, Inc.'s weighted average cost of capital (WACC)?
Protagonist Therapeutics, Inc.'s WACC as of Feb 03, 2025, is 11.39%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Protagonist Therapeutics, Inc.'s cost of equity?
Protagonist Therapeutics, Inc.'s cost of equity is 11.4%, as of Feb 03, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.